THE

DOSE

Daily news for smarter treatment decisions.

Latest Stories

Editorial cartoon: trending up arrow on teal/yellow waves

Novo's Oral Semaglutide First to Show Promise for Kids with Type 2 Diabetes

Novo Nordisk's PIONEER TEENS trial shows oral semaglutide reduced blood sugar by 0.83% in kids aged 10-17, potentially becoming the first oral GLP-1 for pediatric diabetes.

RC Nelson·Apr 24, 2026

GLP-1 Pioneers Propose Radical Shift: Drop GLP-1 Entirely for Weight Loss

By RC Nelson

Why 1 in 10 People May Be Genetically Resistant to GLP-1 Drugs Like Ozempic

By The Dose

Landmark Study Reveals GLP-1 Drugs' Surprising Health Benefits Beyond Weight Loss

By The Dose

Editorial cartoon: lab flask with cross on teal/blue shapes

The Dose

Retatrutide Delivers Record 2% A1C Drop and 16.8% Weight Loss in Diabetes Trial

By RC Nelson·Apr 13, 2026

The Dose

Genetics May Predict Your GLP-1 Drug Response, Landmark Study Shows

By RC Nelson·Apr 9, 2026

The Dose

Lilly's Retatrutide Delivers Record 28.7% Weight Loss in First Phase 3 Trial

By The Dose·Apr 3, 2026

The Dose

Eli Lilly's Triple Agonist Retatrutide Achieves 2% A1C Drop in Phase 3

By The Dose·Mar 30, 2026